Trial
NCT03808168
Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia
Phase IIWITHDRAWNREGULATORYConfidence: MEDIUM
Sponsor
University of Texas Southwestern Medical Center
Collaborators
—
Condition
Cervix Uteri--Diseases
Intervention
Nivolumab
Why stopped
FDA has withdrawn the IND application- requesting protocol changes
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-18